Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, multiple ascending dose escalation, phase 1 study will evaluate KSI-501 in patients with diabetic macular edema. an open-label, multiple ascending dose study

Trial Profile

An open-label, multiple ascending dose escalation, phase 1 study will evaluate KSI-501 in patients with diabetic macular edema. an open-label, multiple ascending dose study

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 02 May 2024 According to Kodiak media release,data from this study will be presented at Association for Research in Vision and Ophthalmology 2024 Annual Meeting, being held from May 5-9 in Seattle, Washington.
  • 30 Jan 2024 According to a Kodiak Sciences media release, results of this study will be presented at the Angiogenesis, Exudation, and Degeneration 2024 virtual meeting on Saturday, February 3, 2024, at 3:30 PM ET.
  • 14 Nov 2023 According to a Kodiak Sciences media release, clinical data are expected to be presented in the first quarter of 2024 at an upcoming scientific meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top